AMA Calls for Ban on 7-OH Products, Highlights Risks to Children

Why it matters

The American Medical Association is the nation's largest and most influential physician organization; its formal call for a ban on 7-OH products and urgent concern about pediatric exposures carries significant weight with FDA regulators, state legislators, and clinical practitioners.

The big picture

At its annual meeting, the AMA expanded its kratom policy to specifically target concentrated 7-hydroxymitragynine (7-OH), which is synthetically derived and can be dramatically more potent than natural kratom. Increasingly, 7-OH products are being manufactured in candy-like forms — gummies, brightly colored packaging, bubblegum-style presentations — raising urgent concerns about accidental pediatric exposures and intentional use by minors. The AMA's action comes amid a wave of state bans and FDA warnings on 7-OH that began in mid-2025.

Key findings

• The AMA adopted new policy calling for a ban on the sale, distribution, or marketing of 7-OH products and similar concentrated kratom derivatives
• The AMA urges FDA and state legislatures to classify 7-OH products as adulterated or misbranded when sold in child-friendly forms
• Manufacturers are extracting and concentrating 7-OH to create products significantly more potent than traditional kratom leaf
• Many 7-OH products are marketed in forms that appeal to young people, including flavored gummies and brightly colored packaging resembling candy
• The AMA continues to support rigorous scientific research to determine safety and efficacy before any decisions on controlled substance scheduling

What they say

"Concentrated 7-OH products are being sold in forms that can resemble candy and other treats, creating unnecessary risks for young people. We share the FDA's concerns and support policies that protect children from exposure to these potentially harmful products," said Dr. Melissa J. Garretson, a member of the AMA Board of Trustees.

Bottom line

With the AMA formally backing a ban on concentrated 7-OH products, the nation's leading physician organization has joined the FDA and dozens of states in treating synthetic kratom derivatives as an urgent public health hazard requiring immediate regulatory action.